Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice

BACKGROUND: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYNOTE-045. The aim of this study was to evaluate the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Med Res
Egile Nagusiak: Furubayashi, Nobuki, Kuroiwa, Kentaro, Tokuda, Noriaki, Tomoda, Toshihisa, Morokuma, Futoshi, Hori, Yoshifumi, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Nakamura, Motonobu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elmer Press 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7239584/
https://ncbi.nlm.nih.gov/pubmed/32489505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr4162
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak